Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by OrthoPediatrics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: OrthoPediatrics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 1:56 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001425450-26-000070
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Sales and marketing | 21,294 | 19,103 | 39,764 | 35,675 |
| General and administrative | 32,814 | 30,443 | 63,837 | 60,723 |
| Restructuring | 1 | 2,971 | 1 | 3,011 |
| Research and development | 2,325 | 2,159 | 4,556 | 4,510 |
| Total operating expenses | 56,434 | 54,676 | 108,158 | 103,919 |
| Operating loss | (4,068) | (10,657) | (12,402) | (21,638) |
| Other expense (income): | ||||
| Interest expense, net | 2,528 | 1,116 | 4,631 | 2,242 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is OrthoPediatrics's R&D?
- OrthoPediatrics (KIDS) reported R&D of $2.33M in Q2 2026.
- How has OrthoPediatrics's R&D changed year-over-year?
- OrthoPediatrics's R&D increased by 7.7% year-over-year, from $2.16M to $2.33M.
- What is the long-term trend for OrthoPediatrics's R&D?
- Over 4 years (2021 to 2025), OrthoPediatrics's R&D has grown at a 13.2% compound annual growth rate (CAGR), from $5.54M to $9.1M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about OrthoPediatrics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude